



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Attorney Docket No: Q89732
SAHNI et al. Confirmation No.: 5356
Filed: August 27, 2001 Application. Serial No.: 09/940,235
Group Art Unit: 1656
Examiner: SWOPE

For: NOVEL CLOT-SPECIFIC STREPTOKINASE PROTEINS POSSESSING ALTERED PLASMINOGEN ACTIVATION CHARACTERISTICS AND A PROCESS FOR THE PREPARATION OF SAID PROTEIN

APPLICANT'S RECORD OF THE SUBSTANCE OF INTERVIEWS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks that summarize the telephone interviews conducted on March 6, 2006 and April 27, 2006 between Dr. Raj Bawa of Bawa Biotechnology Consulting, LLC (the Applicant's representative) and Dr. Kathleen M. Kerr of the US Patent & Trademark Office (SPE of Group Art Unit 1656). Applicants' thank Dr. Kerr for graciously agreeing to review the application file history and for the courtesies extended to Dr. Bawa during the telephone interviews.

Examiner Interview Summary Records (form PTOL-413) dated March 13, 2006 and May 1, 2006 have been received.

REMARKS

I. Interview Conducted March 6, 2006

During the interview conducted on March 6, 2006, the following was discussed:

- 1) Brief description of any exhibits or demonstration: None
- 2) Identification of claims discussed: All pending claims (i.e., claims 34-54).
- 3) Identification of prior art: N/A
- 4) Principle proposed amendments of a substantive nature: None
- 5) Brief identification of principle arguments presented to Examiner Kerr:

The Applicant's representative requested that Examiners Kerr and Swope review all pending objections and rejections of record in the Final Office Action mailed on February 10, 2006. The Applicant's representative emphasized that many objections raised in the Final Office Action had previously been addressed, and that many rejections set forth in the Final Office Action warranted a critical review.

Examiner Kerr agreed to review the Final Office Action mailed February 10, 2006 vis-à-vis the prosecution history. Examiner Kerr informed Dr. Bawa that "...the previous Office action of record is under consideration [and that] a phone call to produce an allowance or a new Office action will be forth coming."

- 6) Other pertinent matters discussed: None
- 7) Overall result(s) of the interview: No specific agreement was reached (other than that indicated above in item no. 5).

II. Interview Conducted April 27, 2006

During the interview conducted on **April 27, 2006**, the following was discussed:

- 1) Brief description of any exhibits or demonstration: None
- 2) Identification of claims discussed: All pending claims (i.e., claims 34-54).
- 3) Identification of prior art: N/A
- 4) Principle proposed amendments of a substantive nature: None
- 5) Brief identification of principle arguments presented to Examiner Kerr:

It was requested that Examiners Kerr and Swope review all pending objections and rejections addressed in the "Supplemental" Final Office Action mailed on April 17, 2006, which replaced previously issued Final Office Action mailed on February 10, 2006. It was pointed out that this "Supplemental" Final Office Action still failed to appreciate that most of the objections had previously been addressed, and that the rejections of record warranted review.

- 6) Other pertinent matters discussed: None.
- 7) Overall result(s) of the interview: As set forth in the Examiner's Interview Summary, Examiner Kerr reviewed the outstanding "Supplemental" Final Office Action and withdrew objections previously overcome by the Applicants. Examiner Kerr invited the Applicants to submit an Amendment for consideration that (i) overcomes all pending rejections and objections; and (ii) simplifies the issues of record.

It is respectfully submitted that the instant "APPLICANT'S RECORD OF THE SUBSTANCE OF INTERVIEWS" complies with the requirements of 37 CFR §§ 1.2 and 1.133 and MPEP § 713.04. No petition or fee is required at this time. However, the USPTO is directed and authorized to charge any unpaid fees, except for the Issue Fee and the

Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

Bawa Biotechnology Consulting, LLC
21005 Starflower Way
Ashburn, VA 20147
Telephone: (703) 582-1745
Facsimile: (571) 223-1844



Raj Bawa, PhD
Registration No. 51,385

Sughrue Mion, PLLC
2100 Pennsylvania Avenue, NW
Washington, DC 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860



Mark L. Hayman, PhD, JD
Registration No. 51,793

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: July 7, 2006